Skip to content
TRENDING
Business

Africa’s Medicine Industry Could Become A Massive Economic Engine

· 4 min read
Africa Medicine Industry
Africa Medicine Industry

Africa’s Medicine Industry Could Become A Massive Economic Engine

Africa imports most of the medicine it uses. During the COVID-19 pandemic, the consequences of that dependence became impossible to ignore.

Countries struggled to access vaccines. Supply chains broke down. Wealthier nations secured stock first while many African countries waited. Years later, that experience is still shaping conversations around health, manufacturing and economic policy across the continent.

Now, governments, development institutions and private sector players are trying to change that story.

Launched in Nairobi this week, the Africa Initiative for Medical Access and Manufacturing (AIM2030) wants to double pharmaceutical manufacturing capacity in Africa by the end of the decade. But beyond health care, the initiative is being positioned as something bigger: an industrial and economic strategy that could reshape parts of Africa’s manufacturing sector.

Africa Still Depends Heavily on Imported Medicine

Today, African countries import between 70% and 100% of finished pharmaceutical products. Vaccine production is even lower. Less than 1% of vaccines used on the continent are produced locally.

That dependence creates vulnerability during global crises. It also means billions of dollars leave African economies each year through imports.

The AIM2030 initiative argues that local production can help solve several problems at once. Stronger regional manufacturing could improve access to medicines, reduce exposure to global supply shocks, create jobs and support industrial growth.

Speaking during the launch, IFC Managing Director Makhtar Diop said the conversation goes far beyond public health.

“This is about health security. But it is also about jobs, investment, industrial growth, and economic resilience,” he said.

That statement captures the wider ambition behind AIM2030.

A Health Initiative With Industrial Ambitions

AIM2030 is backed by the World Bank Group and the African Union Commission, alongside governments, investors and regional health bodies including Africa CDC and the Africa Medicines Agency.

The initiative will initially focus on scaling manufacturing capacity in Egypt, Ethiopia, Ghana, Kenya, Morocco, Nigeria, Rwanda, Senegal and South Africa.

The goal is straightforward on paper: increase African production of medicines, vaccines, diagnostics and medical supplies.

But the economic implications stretch much further.

Pharmaceutical manufacturing supports large supply chains. It creates demand for packaging, transport, logistics, research, warehousing, technology, energy and skilled labour. It also attracts private investment into industrial infrastructure.

For countries trying to grow local industries and reduce import dependence, health manufacturing presents a major opportunity.

Solar-Powered Pediatric Theatre Opens in Kimilili

Why Investors and Entrepreneurs Are Paying Attention

Healthcare demand across Africa continues to rise as populations grow and urbanise. At the same time, governments are under pressure to strengthen local health systems and prepare for future emergencies.

That creates room for investment across multiple sectors tied to pharmaceutical production.

Manufacturing plants need industrial parks, energy infrastructure, transport networks, cold-chain logistics, financing and digital systems. Research institutions and startups also stand to benefit as governments push for regional production capacity.

For young professionals, the shift could create demand for scientists, engineers, technicians, software developers, supply chain specialists and manufacturing talent.

The conversation is increasingly moving away from aid and toward long-term industrial capacity.

“Resilience cannot be imported in the middle of a crisis. It must be built in advance,” Diop said during the launch event in Nairobi.

The Hard Part Comes Next

The ambition behind AIM2030 is significant, but Africa’s pharmaceutical industry still faces major structural barriers.

Manufacturing costs remain high in many countries. Energy reliability continues to be a challenge. Regulatory systems differ across markets, making regional scale difficult. Many countries also lack the large procurement systems needed to support stable local production.

Access to financing remains another hurdle for manufacturers trying to compete with cheaper imports from larger global producers.

That means success will depend heavily on execution, policy coordination and long-term political support.

Still, momentum around local manufacturing is growing across the continent, particularly after the lessons of the pandemic.

For many governments, the question is no longer whether Africa should build stronger pharmaceutical capacity. The focus now is how quickly it can happen and who benefits from it first.

A Shift Bigger Than Healthcare

What AIM2030 represents is a broader shift in how African development is being discussed.

Health is increasingly being linked to manufacturing.
Manufacturing is being linked to jobs.
And jobs are being linked to economic resilience.

That changes the conversation from emergency response to long-term economic strategy.

If the initiative succeeds, Africa’s medicine industry may stop being viewed simply as a healthcare issue and start becoming one of the continent’s most important industrial growth sectors.

Follow us on Twitter and Facebook for more updates.

WRITTEN BY Nairobi Lifestyle Editor
More from Nairobi

Join the conversation

Your email address will not be published. Required fields are marked *

Keep reading

Back to home

Nairobi, straight to your inbox.

The best of the city’s events, culture, money and tech, picked by our editors.

No spam. Unsubscribe any time.